Korean Govt Touts M&A As Fastest Pharma Route Into China
This article was originally published in PharmAsia News
Amid the South Korean government's recent drive to encourage pharma firms to shift their focus to overseas markets, an official at the country's state-owned health industry institute has suggested the industry should seek mergers and acquisitions or joint ventures to advance into the rapidly growing Chinese pharma market.
You may also be interested in...
Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.
A trade institute's recent report emphasizes that government support is still needed although South Korean CRO industry has grown sharply in recent years and suggests ways to improve global competitiveness.
Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.